Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.

Am J Health Syst Pharm

Rusol Karralli, Pharm.D., M.S., is Manager, 340B Education and Compliance Support, 340B Prime Vendor Program, Apexus, Irving, TX. At the time of writing Dr. Karralli was Postgraduate Year 2 Health-System Pharmacy Administration Resident, Memorial Hermann Health System, Houston, TX. Joyce Tipton, B.S.Pharm., M.B.A., FASHP, is Director of Pharmacy and Respiratory Services, Memorial Hermann Memorial City Medical Center, Houston. Doina Dumitru, Pharm.D., M.B.A., FASHP, is Director of Pharmacy, Memorial Hermann The Woodlands, The Woodlands, TX. Lisa Scholz, Pharm.D., M.B.A., is Chief Operating Officer/Chief Pharmacy Officer, Safety Net Hospitals for Pharmaceutical Access, Washington, DC. Santhi Masilamani, Pharm.D., M.B.A., CDE, is Director, Ambulatory Care Advanced Pharmacy Practice Experiences, and Clinical Assistant Professor, University of Houston College of Pharmacy.

Published: September 2015

Purpose: An electronic tool to support hospital organizations in monitoring and addressing financial and compliance challenges related to participation in the 340B Drug Pricing Program is described.

Summary: In recent years there has been heightened congressional and regulatory scrutiny of the federal 340B program, which provides discounted drug prices on Medicaid-covered drugs to safety net hospitals and other 340B-eligible healthcare organizations, or "covered entities." Historically, the 340B program has lacked a metrics-driven reporting framework to help covered entities capture the value of 340B program involvement, community benefits provided to underserved populations, and costs associated with compliance with 340B eligibility requirements. As part of an initiative by a large health system to optimize its 340B program utilization and regulatory compliance efforts, a team of pharmacists led the development of an electronic dashboard tool to help monitor 340B program activities at the system's 340B-eligible facilities. After soliciting input from an array of internal and external 340B program stakeholders, the team designed the dashboard and associated data-entry tools to facilitate the capture and analysis of 340B program-related data in four domains: cost savings and revenue, program maintenance costs, community benefits, and compliance.

Conclusion: A large health system enhanced its ability to evaluate and monitor 340B program-related activities through the use of a dashboard tool capturing key metrics on cost savings achieved, maintenance costs, and other aspects of program involvement.

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp140567DOI Listing

Publication Analysis

Top Keywords

340b program
24
340b
11
program
10
340b drug
8
drug pricing
8
pricing program
8
program involvement
8
community benefits
8
large health
8
health system
8

Similar Publications

Introduction: Oral targeted therapies are a standard of care for men with advanced prostate cancer. However, these therapies are expensive, which may be a barrier to some, particularly the most economically disadvantaged. Through investment in programs to assist this population, savings generated from the 340B program have the potential to mitigate barriers to initiating treatment with targeted therapies in these men.

View Article and Find Full Text PDF

Recent court ruling could increase the size and administrative complexity of the 340B program.

Health Aff Sch

December 2024

Department of Economics and Brooks School of Public Policy, Cornell University, Ithaca, NY 14853, United States.

The 340B program allows certain hospitals and clinics to use outpatient drugs purchased at substantial discounts on insured patients, generating profits to fund care. The size of these profits depends on the number of prescriptions filled by participating hospital or clinics' insured patients that also meet the Health Resources and Services Agency's definition of an eligible patient. A recent court case has challenged the Agency's longstanding definition of a patient, resulting in new definition that could significantly expand the size of the program and create conflicts when an insured patient satisfies the new definition for more than one hospital or clinic participating in the program.

View Article and Find Full Text PDF

Access to essential medications remains a challenge, especially among socioeconomically disadvantaged populations. In 2021, 18 million U.S.

View Article and Find Full Text PDF

Importance: The 340B program provides discounts on outpatient drugs to certain hospitals and federally supported clinics (covered entities) that can be used to generate revenue to fund safety net care. While numerous studies have found no association between 340B and safety net care provision for most hospital covered entities, less is known about whether federally qualified health centers (FQHCs), the largest group of covered entities after hospitals, use the program to enhance safety net care.

Objective: To assess whether a proxy for 340B revenue was associated with increased safety net care provision among FQHCs.

View Article and Find Full Text PDF

Introduction: The use of expensive oral targeted agents for advanced prostate cancer can be influenced by those who stand to gain from their use. The 340B drug pricing program allows eligible hospitals to purchase medications at steep discounts, generating millions of dollars in savings. The extent to which hospitals engage in higher-risk prescribing due to program incentives is unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!